On May 21, 2018, the U.S. Food and Drug Administration (FDA) approved avatrombopag (Doptelet) tablets for the treatment of thrombocytopenia (low platelet count) in adult patients with chronic liver disease scheduled for medical or dental surgery. This is the first time the FDA has approved a drug for this indication.
With this latest FDA approval, adult patients with chronic liver disease planning medical or dental surgery can finally undergo the procedure with a more ideal platelet count. The availability of this new drug not only brings new hope to this group of patients but also provides clinicians with new options for clinical practice. Avatrombopag (Doptelet) tablets are primarily used to treat thrombocytopenia in adult patients with chronic liver disease scheduled for medical or dental surgery.
According to Dr. Richard Pazdur, Director of the FDA's Center for Oncology Excellence and the Office of Hematologic Oncology Products at the FDA's Center for Drug Evaluation and Research, patients with chronic liver disease and low platelet counts who require medical attention have a significantly increased risk of bleeding. Recent research has clarified whether avatrombopag (Doptelet) can provide a relatively safe increase in platelet counts. It can not only reduce but also eliminate the need for platelet transfusions, thus avoiding potential infections and other adverse reactions associated with platelet transfusions.
Clinical Studies of Avatrombopag (Doptelet)
Based on two clinical trials (ADAPT-1 and ADAPT-2) involving 435 patients with chronic liver disease and severe thrombocytopenia, preliminary results demonstrate that avatrombopag (Doptelet) has a good safety profile and high efficacy in improving platelet function in these patients, and can significantly replace planned platelet transfusions for these patients. Through 5 consecutive days of two different doses of avatrombopag (Doptelet)... Ultimately, controlled oral administration trials revealed a significant difference in efficacy compared to placebo (no treatment). Compared to the placebo group, treatment with both doses of avatrombopag (Doptelet) significantly increased platelet counts on the day of the procedure and within 7 days post-procedure, and significantly increased the proportion of patients requiring no platelet transfusions or rescue treatment.
Avatrombopag (Doptelet) Side Effects
Common side effects of avatrombopag (Doptelet) The effects are significant; almost all patients undergoing treatment with this drug experience a range of adverse reactions, including mild bleeding, dry mouth, constipation, and intestinal irritation. Constipation is the most common, affecting almost all patients; statistics show that approximately 85% of patients experience this adverse reaction.
As shown in clinical trial reports for the common drug avatrambopag (Doptelet), its most common adverse reactions include fever, abdominal pain, nausea, headache, general weakness, and edema of the extremities. However, it is worth noting that patients with pre-existing chronic liver disease or specific coagulation disorders may have an increased risk of thrombosis from taking avatrambopag (Doptelet).
Avatrambopag (Doptelet) has been granted priority review status by the FDA, meaning that the FDA will make a final approval decision for this type of new drug within the next six months. Priority review is given to drugs that, if approved, would significantly improve the safety or efficacy in the treatment, diagnosis, or prevention of certain serious diseases.
